- Amarin Reports First Quarter 2024 Business Update and Financial Results
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event
- Amarin Announces Results of Annual General Meeting of Shareholders
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024
More ▼
Key statistics
As of last trade, Amarin Corporation PLC (EH3A:DEU) traded at 0.855, 44.92% above the 52 week low of 0.590 set on Nov 14, 2023.
52-week range
Open | 0.80 |
---|---|
High | 0.86 |
Low | 0.80 |
Bid | 0.85 |
Offer | 0.87 |
Previous close | 0.80 |
Average volume | 4.07k |
---|---|
Shares outstanding | 410.67m |
Free float | 390.11m |
P/E (TTM) | -- |
Market cap | 344.68m USD |
EPS (TTM) | -0.1045 USD |
Data delayed at least 15 minutes, as of Apr 30 2024.
More ▼